
EU Approves Pfizer’s RSV Vaccine ABRYSVO for Adults 18-59
Pfizer Inc. announced that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO, the company’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, to extend the indication to include …